BioMarin’s $1m Gene Therapy Roctavian Hits Payer Problems In Germany
Doubts About Blockbuster Prospects Linger
BioMarin has yet to treat a patient with Roctavian, the first ever hemophilia A gene therapy, eight months after its first approval in Europe, as pricing delays cloud its commercial prospects.
